MSD and kangfang biology announced an important cooperation in the field of tumor immunotherapy

Source: Biovalley 2015-12-04 (December 4, 2015, Zhongshan, Guangdong Province, China), Zhongshan kangfang biomedical Co., Ltd (hereinafter referred to as "kangfang biology") located in the national health base, today announced that it has been working with moxa East (NYSE: MRK) Merck) in the United States and Canada reached a cooperation on the research, development and promotion of a tumor immunotherapy According to this Agreement: MSD will obtain the global exclusive development and promotion right of kangfang biological compound ak-107 Ak-107 is an immunocheckpoint blocking antibody discovered by kangfang biology in China and used for tumor immunotherapy According to the terms of the cooperation agreement, kangfangbio will receive an initial payment from MSD and a phased payment with a total price of US $200 million covering development and promotion More details have not been disclosed "We are very pleased to work with global leader in tumor immunotherapy, MSD Through this cooperation, we will combine the unique bio pharmaceutical development and R & D platform of kangfang biology with the mature late clinical trials and commercial advantages of MSD to accelerate the process of ak-107 entering the global market This collaboration demonstrates our company's commitment to bring innovative therapies to the market to meet the urgent medical needs of cancer patients around the world Dr Xia Yu, chairman and CEO of kangfang biology, said: "kangfang biology looks forward to cooperation with MSD, and we will continue to expand cooperation opportunities in the field of innovative biopharmaceuticals "This cooperation with kangfang biology is based on our existing strength in the field of tumor immunology We will continue to focus on improving the treatment level of tumor patients by stimulating the tumor specific immune response mechanism "Dr Eric Rubin, vice president of MSD company and head of cancer early development stage treatment field of MSD laboratory, said," the immune checkpoint block antibody ak-107 added, further consolidating our commitment to explore joint treatment across cancer species "